Steven Kanner
Chief Tech/Sci/R&D Officer at CARIBOU BIOSCIENCES, INC.
Net worth: 2 M $ as of 31/03/2024
Profile
Steven B.
Kanner is currently an Independent Director at Specific Biologics, Inc. since 2023 and the Chief Scientific Officer at Caribou Biosciences, Inc. since 2017.
Previously, he worked as the Vice President & Head-Biology at Arrowhead Pharmaceuticals, Inc. from 2013 to 2017.
He completed his undergraduate degree at the University of California, Berkeley and obtained doctorate degrees from the University of Miami and The University of Miami Leonard M.
Miller School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 20/02/2024 | 387,037 ( 0.43% ) | 2 M $ | 31/03/2024 |
Steven Kanner active positions
| Companies | Position | Start |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/06/2017 |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Director/Board Member | 10/10/2023 |
Former positions of Steven Kanner
| Companies | Position | End |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/06/2017 |
Training of Steven Kanner
| University of California, Berkeley | Undergraduate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Stock Market
- Insiders
- Steven Kanner
